Key points are not available for this paper at this time.
Artificial Intelligence (AI) is transforming the pharmaceutical industry, revolutionizing drug discovery, development, and patient care. This comprehensive review explores the diverse applications of AI in the pharmaceutical sector, discussing its advantages, challenges, and future prospects. AI-driven techniques, including machine learning and deep learning, have accelerated drug discovery processes by expediting target identification, virtual screening, and drug repurposing. Predictive analytics optimize clinical trial design, while personalized medicine leverages patient-specific data for precise treatment plans. AI enhances drug formulation and manufacturing, improves pharmacovigilance and drug safety, and supports drug pricing and market access strategies. Despite its potential, challenges such as ethical considerations and data privacy concerns must be addressed. The integration of AI into existing workflows and regulatory compliance remain areas of focus. By overcoming these challenges, AI stands poised to reshape the pharmaceutical industry and pave the way for a more efficient, personalized, and impactful approach to drug development and healthcare.
G Nihalani (Thu,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: